PFSA (Profusa) ROC (Joel Greenblatt) %: -16,469.46% (As of Mar. 2026)


PFSA Profusa Inc PFSA
8 GF Score
Price $2.10
! 3 Warning Signs
View Full Analysis

What is Profusa ROC (Joel Greenblatt) %?

Profusa PFSA -16.54% 8 ROC (Joel Greenblatt) % is -16,469.46% as of Mar. 2026. GuruFocus rates PFSA with a GF Score™ of 8/100. The stock has 3 warning signs investors should review. Among 839 Medical Devices & Instruments companies, Profusa ranks worse than 99.64% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Profusa's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -16,469.46%.

The historical rank and industry rank for Profusa's ROC (Joel Greenblatt) % or its related term are showing as below:

PFSA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -416275   Med: -240300   Max: -61.63
Current: -41880.24

During the past 5 years, Profusa's highest ROC (Joel Greenblatt) % was -61.63%. The lowest was -416275.00%. And the median was -240300.00%.

PFSA's ROC (Joel Greenblatt) % is ranked worse than
99.64% of 839 companies
in the Medical Devices & Instruments industry
Industry Median: 3.94 vs PFSA: -41880.24

Profusa's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Profusa  (NAS:PFSA) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Profusa ROC (Joel Greenblatt) % Related Terms


Profusa ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Profusa's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Profusa ROC (Joel Greenblatt) % Chart

Profusa Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
-61.63 -137.94 -299,900.00 -240,300.00 -416,275.00

Profusa Quarterly Data
Dec21 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -427,100.00 -16,469.46

PFSA vs ODYY, SSKN, NUMD: ROC (Joel Greenblatt) % Comparison

For the Medical Devices subindustry, Profusa's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Profusa ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Profusa's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Profusa's ROC (Joel Greenblatt) % falls into.


PFSA
8GF Score
Profusa Inc PFSA
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Profusa ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.986) - (11.254 + 0 + 4.066)
=-13.334

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.287) - (12.332 + 0 + 4.151)
=-16.196

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Profusa for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-13.752/( ( (0.008 + max(-13.334, 0)) + (0.159 + max(-16.196, 0)) )/ 2 )
=-13.752/( ( 0.008 + 0.159 )/ 2 )
=-13.752/0.0835
=-16,469.46 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -16,469.46% mean?
Profusa (PFSA) has a ROC (Joel Greenblatt) % of -16,469.46% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Profusa and its competitors. According to the industry distribution chart, Profusa ranks #836 out of 839 companies in the Medical Devices & Instruments industry, placing it in the top 99.6%.
Is Profusa's ROC (Joel Greenblatt) % too high?
Profusa's current ROC (Joel Greenblatt) % is -16,469.46%. Based on the distribution chart, Profusa ranks #836 out of 839 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Profusa has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Profusa's ROC (Joel Greenblatt) % compare to ODYY and SSKN?
According to the Medical Devices & Instruments industry distribution chart, Profusa ranks #836 out of 839 companies for ROC (Joel Greenblatt) %. This places Profusa in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 3.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 3.94, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Profusa and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 3.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profusa's current ROC (Joel Greenblatt) % is -16,469.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profusa stock overvalued right now?
Profusa (PFSA) has a current ROC (Joel Greenblatt) % of -16,469.46%. The current ROC (Joel Greenblatt) % is -16,469.46%. Profusa's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Profusa (PFSA), the current ROC (Joel Greenblatt) % is -16,469.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Profusa Business Description

Address 626 Bancroft Way, Suite A, Berkeley, CA, USA, 94710
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
8GF Score

Get the complete analysis for PFSA

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price